177 related articles for article (PubMed ID: 20142182)
1. Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on renal function in patients with ST-segment elevation myocardial infarction treated with primary or rescue percutaneous coronary intervention.
Osherov AB; Roguin A; Aronson D; Grenadier E; Kerner A; Boulus M; Kapeliovich M; Hani A; Hammerman H; Beyar R; Nikolsky E
EuroIntervention; 2009 Nov; 5(5):604-9. PubMed ID: 20142182
[TBL] [Abstract][Full Text] [Related]
2. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
[TBL] [Abstract][Full Text] [Related]
3. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of glycoprotein IIb/IIIa receptor antagonists for patients undergoing percutaneous coronary intervention within twelve hours of fibrinolysis.
Belle L; Fourny M; Reynaud T; Hammer L; Vanzetto G; Labarère J;
Catheter Cardiovasc Interv; 2011 Sep; 78(3):376-84. PubMed ID: 21413113
[TBL] [Abstract][Full Text] [Related]
5. Sex-based differences in clinical and angiographic outcomes in patients with ST-elevation myocardial infarction treated with concomitant use of glycoprotein IIb/IIIa inhibitors.
Kralev S; Hennig O; Lang S; Kälsch T; Borggrefe M; Dempfle CE; Süselbeck T
Cardiol J; 2010; 17(6):580-6. PubMed ID: 21154260
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry.
Lopes RD; Peterson ED; Chen AY; Roe MT; Wang TY; Ohman EM; Magid DJ; Ho PM; Wiviott SD; Scirica BM; Alexander KP
JACC Cardiovasc Interv; 2010 Jun; 3(6):669-77. PubMed ID: 20630461
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
8. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
Mehran R; Nikolsky E; Lansky AJ; Kirtane AJ; Kim YH; Feit F; Manoukian S; Moses JW; Ebrahimi R; Ohman EM; White HD; Pocock SJ; Dangas GD; Stone GW
JACC Cardiovasc Interv; 2009 Aug; 2(8):748-57. PubMed ID: 19695543
[TBL] [Abstract][Full Text] [Related]
9. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction--a meta-regression of randomized controlled trials.
Sethi A; Bajaj A; Bahekar A; Bhuriya R; Singh M; Ahmed A; Khosla S
Catheter Cardiovasc Interv; 2013 Aug; 82(2):171-81. PubMed ID: 22961908
[TBL] [Abstract][Full Text] [Related]
11. Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.
De Luca G; van't Hof AW; Huber K; Gibson CM; Bellandi F; Arntz HR; Maioli M; Noc M; Zorman S; Secco GG; Zeymer U; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Dudek D
Heart Vessels; 2014 Jan; 29(1):15-20. PubMed ID: 23494604
[TBL] [Abstract][Full Text] [Related]
12. The ratio of contrast volume to glomerular filtration rate predicts in-hospital and six-month mortality in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
Çiçek G; Bozbay M; Açıkgöz SK; Altay S; Uğur M; Köroğlu B; Uyarel H
Cardiol J; 2015; 22(1):101-7. PubMed ID: 24671903
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.
De Luca G; Gibson CM; Bellandi F; Noc M; Dudek D; Zeymer U; Arntz HR; Cutlip D; Maioli M; Zorman S; Mesquita Gabriel H; Emre A; Rakowski T; Gyongyosi M; Huber K; Van't Hof AW
Atherosclerosis; 2009 Nov; 207(1):181-5. PubMed ID: 19426981
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors.
Kralev S; Krause B; Papavassiliu T; Lang S; Haghi D; Kälsch T; Dempfle CE; Borggrefe M; Süselbeck T
Cardiol J; 2009; 16(3):234-40. PubMed ID: 19437397
[TBL] [Abstract][Full Text] [Related]
15. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
16. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
[TBL] [Abstract][Full Text] [Related]
17. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry.
Safley DM; Venkitachalam L; Kennedy KF; Cohen DJ
JACC Cardiovasc Interv; 2015 Oct; 8(12):1574-82. PubMed ID: 26493250
[TBL] [Abstract][Full Text] [Related]
18. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
Rozenman Y; Mehran R; Witzenbichler B; Dangas G; Desaga M; Kochman J; Nilsen DW; Finkelstein A; Mosseri M; Stone GW
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E9-14. PubMed ID: 22511592
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
[TBL] [Abstract][Full Text] [Related]
20. Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.
De Luca G; Gibson M; Cutlip D; Huber K; Dudek D; Bellandi F; Noc M; Maioli M; Zorman S; Zeymer U; Secco GG; Mesquita Gabriel H; Emre A; Arntz HR; Rakowski T; Gyongyosi M; Hof AW;
Arch Cardiovasc Dis; 2013 Mar; 106(3):155-61. PubMed ID: 23582677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
